The crisis caused by increasing placebo response rates in efficacy studies in psychiatry has forced academics and drug companies to relook the science of placebo effects. Clinical response resulting from nonspecific factors (placebo effect) related to the conducting of clinical trials has grown significantly, with effect sizes of placebo groups more than doubling between 1980 and 2005. 1 For some reasons, poorly understood at this point, patients included in randomised controlled trials (RCTs) have become increasingly responsive to nonspecific therapeutic factors inherent in the clinical context in which trials are conducted.
In depression studies a stage has now been reached where drug-placebo separation has become very difficult to achieve. Surprisingly, rigorous research of placebo effects has only gained momentum in the past decade.
Naturalistic studies such as CATIE, 2 STAR-D 3 and BALANCE 4 yielded important information about the comparative effectiveness of currently available treatments. However, these studies also clearly demonstrated a need for more efficacious drugs.
Despite the recent introduction of comparative effectiveness methodologies, RCTs, at least for the time being, are still required for registration purposes and are still regarded as the highest level of evidence of efficacy in psychiatry research.
Unfortunately, the increasing number of failed RCTs in psychotropic drug development during the past decade, in combination with the recent recession, has led some companies to re-allocate resources to other less risky and less costly areas of drug discovery and development. 5 Despite major advances in our understanding of mechanisms involved in psychiatric disorders, central nervous system (CNS) drug development has unfortunately not delivered the anticipated dramatic new developments over the past two or three decades.
Intensive efforts to find more efficacious drugs with novel mechanisms of action notwithstanding, the rate of real innovation in terms of mechanism of action in all major drug classes has been very slow. The problem of failed studies is not new, but has been growing in magnitude for decades. A high placebo effect may be beneficial in clinical settings, but is one of the major causes of study failure and remains a fundamental issue that needs to be dealt with to ensure the future of drug development. 6
What is the placebo response?
What is generally perceived as the placebo response is not necessarily response to placebo. Until recently (and still so in efficacy studies) placebo has been defined by its inert content 
The increased placebo effect
Placebo response rates have increased from approximately 20% in the 1980s, to about 35% during the 1990s, to the current level of between 45% and 48% in depression studies. 6 After three recent important meta-analyses of efficacy of antidepressants in RCTs, the authors suggested that the overall advantage of antidepressants over placebo is trivial. [9] [10] [11] The press then widely reported that antidepressants do not work well and should therefore not be used. What was not conveyed was the fact that the incremental effect of antidepressants relative to placebos increases as the severity of depression increases. The effect of antidepressants Confounding placebo response in clinical trials: Analysing the little we know and current strategies to address the crisis editorial was robust in the severely ill patients (Hamilton Depression Rating Scale >23). The fact that antidepressants performed numerically better than placebo in 75% of the studies analysed by Kirsch et al., 10 while placebo outperformed antidepressants numerically in only one study, was also not highlighted clearly enough. 6 One should also be circumspect about findings from the meta-analysis by Fournier et al., 11 where only 6 out of 2 000 RCTs were included for analysis. 12 If the prevalence of depression is taken into account, the 10 -15%
average drug-placebo difference in modern studies is significant.
One should also remember that the studies included in these meta- A lower probability of placebo allocation (i.e. increased likelihood of being on active drug) has been shown to increase placebo response rates. 14 The mechanism for this is not clear, 
Importance of baseline ratings and quality of interview and raters
Appropriate patient selection is possibly the most important factor in CNS trial success. 6, 15 Avoiding pitfalls relating to patient selection is regarded as the key to solving increased placebo response rates. A considerable body of research has implicated inappropriate patient selection as a major contributing factor to study failure. Strategies aimed at more careful selection of suitable patients are currently being investigated. 16 The debate on the use of centralised (independent) versus on-site raters has not been resolved, as study findings have been inconsistent and limited in number. From the studies comparing the utility of central versus site-attached raters, it is only clear that central and on-site raters rate differently. Differences were pronounced during the early study phases (baseline ratings), but ratings converged progressively as the studies advanced, achieving very low inter-rater variability at study endpoints. 17, 18 At present it is not clear who is more accurate or what could be driving the initial pronounced inter-rater variability at baseline, as neither the central raters nor the raters attached to the sites consistently rated higher or lower across different studies. Baseline score inflation by raters attached to the sites was therefore not found to be a confounding factor across the limited number of studies conducted. Significantly, the placebo response rates were lowest where the two groups had similar baseline ratings.
It is likely that in future additional centralised raters will be employed during early study phases. At this point cross-checking (by an independent rater) of subjects included in trials is seen as a probable solution. Inclusion of a run-in phase has also been implemented to avoid the problem of excessive baseline rating variability. Some current studies have also disconnected the inclusion process from response rating. Efficacy raters are not involved in selection of patients for inclusion in these studies.
Operational oversight with hands-on quality control should be a priority rather than the current emphasis on high turnover, often enforced by unreasonable timelines.
Poor raters or situations where rating skills do not match interviewing skills may also contribute towards increased placebo responses. 15 It is not clear whether placebo response rates for specific raters remain consistent across studies, as these data are often analysed in private and not shared among different sponsors. There seems to be conflicting evidence in this regard, with some investigators consistently showing lower placebo response rates and others varying response rates between studies. 19 Some experts are strongly proposing increased monitoring by the sponsor in the clinical setting of the rating process for single patients.
Inadequacy of current diagnostic categories
The 
